These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 28739436)

  • 1. Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders - A retrospective cohort study in Taiwan.
    Huang SF; Chen MH; Wang FD; Tsai CY; Fung CP; Su WJ
    J Microbiol Immunol Infect; 2018 Dec; 51(6):784-793. PubMed ID: 28739436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
    Lee CK; Wong SHV; Lui G; Tang W; Tam LS; Ip M; Hung E; Chen M; Wu JC; Ng SC
    J Crohns Colitis; 2018 Jul; 12(8):954-962. PubMed ID: 29757355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries.
    Cui X; Gao L; Cao B
    Int J Infect Dis; 2020 Mar; 92S():S37-S40. PubMed ID: 32114201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection.
    Lee EH; Kang YA; Leem AY; Park MS; Kim YS; Kim SK; Chang J; Kim SY
    Sci Rep; 2017 Jul; 7(1):6473. PubMed ID: 28743918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy.
    Ramos GP; Stroh G; Al-Bawardy B; Faubion WA; Papadakis KA; Escalante P
    Inflamm Bowel Dis; 2018 Sep; 24(10):2272-2277. PubMed ID: 29718223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
    Medina-Gil C; Dehesa L; Vega A; Kerdel F
    Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
    Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
    J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
    Getahun H; Matteelli A; Abubakar I; Aziz MA; Baddeley A; Barreira D; Den Boon S; Borroto Gutierrez SM; Bruchfeld J; Burhan E; Cavalcante S; Cedillos R; Chaisson R; Chee CB; Chesire L; Corbett E; Dara M; Denholm J; de Vries G; Falzon D; Ford N; Gale-Rowe M; Gilpin C; Girardi E; Go UY; Govindasamy D; D Grant A; Grzemska M; Harris R; Horsburgh CR; Ismayilov A; Jaramillo E; Kik S; Kranzer K; Lienhardt C; LoBue P; Lönnroth K; Marks G; Menzies D; Migliori GB; Mosca D; Mukadi YD; Mwinga A; Nelson L; Nishikiori N; Oordt-Speets A; Rangaka MX; Reis A; Rotz L; Sandgren A; Sañé Schepisi M; Schünemann HJ; Sharma SK; Sotgiu G; Stagg HR; Sterling TR; Tayeb T; Uplekar M; van der Werf MJ; Vandevelde W; van Kessel F; van't Hoog A; Varma JK; Vezhnina N; Voniatis C; Vonk Noordegraaf-Schouten M; Weil D; Weyer K; Wilkinson RJ; Yoshiyama T; Zellweger JP; Raviglione M
    Eur Respir J; 2015 Dec; 46(6):1563-76. PubMed ID: 26405286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latent Tuberculosis Infection and the Risk of Subsequent Cancer.
    Su VY; Yen YF; Pan SW; Chuang PH; Feng JY; Chou KT; Chen YM; Chen TJ; Su WJ
    Medicine (Baltimore); 2016 Jan; 95(4):e2352. PubMed ID: 26825880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment guidelines for latent tuberculosis infection.
    ;
    Kekkaku; 2014 Jan; 89(1):21-37. PubMed ID: 24654427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective cohort study of latent tuberculosis in adult close contacts of active pulmonary tuberculosis patients in Korea.
    Park SH; Lee SJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Kim HJ; Menzies D
    Korean J Intern Med; 2016 May; 31(3):517-24. PubMed ID: 27052266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High risk for latent tuberculosis infection among medical residents and nursing students in India.
    Kinikar A; Chandanwale A; Kadam D; Joshi S; Basavaraj A; Pardeshi G; Girish S; Shelke S; DeLuca A; Dhumal G; Golub J; Lokhande N; Gupte N; Gupta A; Bollinger R; Mave V
    PLoS One; 2019; 14(7):e0219131. PubMed ID: 31283794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid treatment to prevent TB in kidney and pancreas transplant recipients based on an interferon-γ-releasing assay: an exploratory randomized controlled trial.
    Kim SH; Lee SO; Park IA; Kim SM; Park SJ; Yun SC; Jung JH; Shin S; Kim YH; Choi SH; Kim YS; Woo JH; Park SK; Park JS; Han DJ
    J Antimicrob Chemother; 2015 May; 70(5):1567-72. PubMed ID: 25608587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older.
    Noh CS; Kim HI; Choi H; Kim Y; Kim CH; Choi JH; Hyun IG; Baek MS
    Respir Med; 2019 Oct; 157():52-58. PubMed ID: 31522030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An observational study on prevalence of latent tuberculosis infection and outcome of 3HP treatment in patients under hemodialysis in Taiwan.
    Wu CH; Su HA; Chou CA; Liu JW; Lee CT; Dai LH; Yang CC
    J Formos Med Assoc; 2021 Jun; 120(6):1350-1360. PubMed ID: 34074499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latent Tuberculosis Therapy Outcomes in Dialysis Patients: A Retrospective Cohort.
    Chiang LY; Baumann B; Romanowski K; Kumar D; Campbell JR; Djurdjev O; Morshed M; Sekirov I; Cook VJ; Levin A; Johnston JC
    Am J Kidney Dis; 2021 May; 77(5):696-703. PubMed ID: 32818551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.